Tuesday, October 26, 2021: 5:00 PM-7:00 PM
Exhibit Hall (Rosen Shingle Creek)
Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar
Benjamin M Greenberg, MD, MHS, FANA, FAAN, University of Texas Southwestern Medical Center;
Jerome de Seze, MD, PhD, Hôpital de Hautepierre;
Albert Saiz, MD, PhD, Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona;
Takashi Yamamura, MD, PhD, National Institute of Neuroscience, National Center of Neurology and Psychiatry;
Michael Yeaman, PhD, Department of Medicine, David Geffen School of Medicine at UCLA;
Carole Marcillat, PharmD, F. Hoffmann-La Roche Ltd;
Xiujing Kou, MD, F. Hoffmann-La Roche Ltd;
Kristina Weber, PhD, F. Hoffmann-La Roche Ltd;
Kathleen Blondeau, PhD, F. Hoffmann-La Roche Ltd;
Brian G Weinshenker, MD, FRCP(C), Mayo Clinic;
Francesco Patti, MD, PhD, University of Catania
Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis
Daniel Wynn, MD, Consultants in Neurology MS Center;
Lawrence P Goldstick, MD, University of Cincinnati;
William Bauer, MD, PhD, University of Toledo;
Enxu Zhao, MS, Mallinckrodt Pharmaceuticals;
Eva Tarau, MD, Mallinckrodt Pharmaceuticals;
Jeffrey A. Cohen, MD, Neurological Instiute,Cleveland Clinic;
Derrick Robertson, MD, University of South Florida, Morsani College of Medicine;
Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
